Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with most regaining 5% or less of the pounds they shed. A company-funded ...

Now, there may be another option for him. It's a drug called tirzepatide, also known as Mounjaro or Zepbound. It's FDA approved to manage diabetes and obesity. Now, UC San Diego researchers have ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

The method: Zepbound, 12.5 mg. I was one of the first to try Rybelsus, a pill form of semaglutide, but it made me horribly sick, and you had to take it like half an hour after waking up.

Millions of Americans are on their way to healthier weights. We’re following the big shifts in their lives. A 46-year-old dad tells how his life has changed. (Photo illustration: Yahoo News ...

Eli Lilly and Co.’s Zepbound, for instance, brought in nearly $5 billion in sales in 2024, its first full year on the market. But leading treatments like Zepbound and Novo Nordisk’s Wegovy are ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

Zepbound, which has the same active ingredient, tirzepatide, is the brand name for the U.S. weight loss version, with Mounjaro sold for diabetes there. Lilly offers 5 mg, 7.5 mg and 10 mg vials of ...

Pfizer was already behind the competition. Lilly, whose weekly Zepbound shot rapidly reached nearly $5 billion in annual sales after winning US approval in 2023, also has an oral treatment in the ...